Cardiovascular effects of basal insulins by Mannucci, Edoardo et al.
© 2015 Mannucci et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Drug, Healthcare and Patient Safety 2015:7 113–120
Drug, Healthcare and Patient Safety Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
113
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/DHPS.S43300




1Diabetes Agency, Careggi Teaching 
Hospital, Florence, 2Section of 
endocrinology, Department of 
Biomedical Clinical and experimental 
Sciences, University of Florence  
and Careggi University Hospital, 
Florence, italy
Correspondence: edoardo Mannucci 
Diabetes Agency, Careggi  
Teaching Hospital, Azienda  
Ospedaliero-Universitaria Careggi,  
via delle Oblate 4, Florence 50141, italy 
email edoardo.mannucci@unifi.it
Abstract: Basal insulin is an important component of treatment for both type 1 and type 2 
diabetes. One of the principal aims of treatment in patients with diabetes is the prevention of 
diabetic complications, including cardiovascular disease. There is some evidence, although 
controversial, that attainment of good glycemic control reduces long-term cardiovascular risk 
in both type 1 and type 2 diabetes. The aim of this review is to provide an overview of the 
potential cardiovascular safety of the different available preparations of basal insulin.  Current 
basal insulin (neutral protamine Hagedorn [NPH], or isophane) and basal insulin analogs 
(glargine, detemir, and the more recent degludec) differ essentially by various measures of 
pharmacokinetic and pharmacodynamic effects in the bloodstream, presence and persistence 
of peak action, and within-subject variability in the glucose-lowering response. The currently 
available data show that basal insulin analogs have a lower risk of hypoglycemia than NPH 
human insulin, in both type 1 and type 2 diabetes, then excluding additional harmful effects 
on the cardiovascular system mediated by activation of the adrenergic system. Given that no 
biological rationale for a possible difference in cardiovascular effect of basal insulins has 
been proposed so far, available meta-analyses of publicly disclosed randomized controlled 
trials do not show any signal of increased risk of major cardiovascular events between the 
different basal insulin analogs. However, the number of available cardiovascular events in 
these trials is very small, preventing any clear-cut conclusion. The results of an ongoing clini-
cal trial comparing glargine and degludec with regard to cardiovascular safety will provide 
definitive evidence.
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Introduction
Basal insulin is an important component of treatment for both type 1 diabetes (T1DM) 
and type 2 diabetes (T2DM). In T1DM patients on multiple daily injections, basal 
insulin is combined with prandial (rapid-acting) insulin in basal-bolus schemes; in 
T2DM, basal insulin is used either alone or in combination with non-insulin drugs or 
prandial insulin.
One of the principal aims of treatment in patients with diabetes is the prevention 
of diabetic complications, including cardiovascular disease. There is some evidence, 
although controversial, that the attainment of good glycemic control reduces the 
long-term cardiovascular risk in both T1DM1 and T2DM.2,3 It is also possible that 
glucose-lowering drugs, including insulin, have either beneficial or harmful effects on 
cardiovascular risk independent of their action on blood glucose. On the other hand, 
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could have a negative impact on cardiovascular morbidity 
and/or mortality.2,4,5
The aim of this review is to provide an overview of the 
potential cardiovascular effects of the different available 
preparations of basal insulin.
Clinical pharmacology  
of basal insulins
Current basal insulin (neutral protamine Hagedorn [NPH]) 
and basal insulin analogs (glargine [IGla], detemir [IDet], 
and the more recent degludec [IDeg]) differ essentially by 
various measures of pharmacokinetic and pharmacodynamic 
effects in the bloodstream, presence and persistence of peak 
action, and within-subject variability in the glucose-lowering 
response (Table 1).
NPH consists of a crystalline suspension of human insulin 
with protamine and zinc. This combination determined an 
intermediate-acting insulin with a slower onset of action and 
a longer duration of activity with respect to regular insulin.6 
Conversely, insulin analogs are synthesized with DNA 
recombinant technology and have some chemical modifica-
tions with respect to natural insulin, resulting in an altered 
pharmacokinetic profile:
1. In IGla, asparagine at position 21 in the A subunit is 
replaced with glycine and the carboxyl terminus of the 
B subunit has two additional arginines. These modifica-
tions determine a different isoelectric point, making the 
molecule less soluble at normal pH, resulting in slower 
absorption.7
2. IDet is an acylated human insulin that has slower absorp-
tion in the bloodstream and binds to circulating albumin, 
thus having a longer duration of action than regular 
human insulin.8
3. The protein sequence of IDeg differs from that of human 
insulin for the acylation DesB30 at the amino group of 
LysB29 with hexadecanedioic acid via a gamma-glutamic 
acid linker. IDeg forms multihexamers after subcutane-
ous injection, resulting in a soluble depot with slow and 
continuous absorption into the circulation.9 IDeg reaches 
steady state after 3 days of administration in a once-daily 
scheme. The duration of action of IDeg is longer, and the 
day-to-day variability of absorption is less in comparison 
with any other basal insulin.10
Clinical trials comparing  
basal insulins
Glargine versus NPH
Nine randomized controlled trials (RCTs) have compared 
the efficacy of IGla and NPH in T1DM. Despite the fact 
that in all trials both insulins were titrated aiming at optimal 
glucose control, IGla was associated with an improvement 
of fasting plasma glucose in most studies,11–14 although not 
all,15 whereas glycated hemoglobin was slightly improved11,12 
or unchanged.13,14,16 Interestingly, despite the trend toward 
improved glucose control, IGla was not associated with an 
increased risk of hypoglycemia;17 in contrast, some trials 
reported a reduction in nocturnal hypoglycemia.11,12,14,16
A larger number of trials have investigated the effect of 
IGla versus that of NPH in T2DM.18 Most were designed as 
treat-to-target trials, in which both insulins were titrated to 
reach strict control of fasting plasma glucose. When added 
to oral hypoglycemic drugs without prandial insulin, IGla 
showed a lower incidence of nocturnal hypoglycemia than 
NPH, with similar overall glucose control.19–22 A similar 
reduction of hypoglycemic risk was observed in trials in 
which basal insulin was combined with prandial insulin in 
T2DM.23–25
Detemir versus NPH
In T1DM, glycated hemoglobin is either reduced26–28 or 
unchanged29–31 with IDet in comparison with NPH insulin; 
such improvement, when present, appears to be due to lower 
levels of fasting plasma glucose. In addition, IDet is associ-
ated with a reduced risk of hypoglycemia.26–31 Furthermore, 
all RCTs are concordant in showing a significant difference 
in weight gain in patients with T1DM on IDet, with a mean 
weight reduction ranging between 0.5 kg and 1.7 kg versus 
NPH. A similar reduction in hypoglycemic risk and weight 
gain was observed in poorly controlled insulin-naïve T2DM 
patients on oral antidiabetic drug therapy where IDet and 
NPH insulin were added to their oral therapy,32,33 or when IDet 
and NPH were combined with prandial insulin in patients 
already treated with insulin.34–36
Detemir versus glargine
In a euglycemic glucose clamp study, IDet was  associated 
with lower within-subject variability in comparison 
Table 1 Pharmacokinetic parameters for basal insulin preparations




Duration of  
action (hours)
Regular basal NPH 1–3 4–8 13–18
Glargine 2–4 None .24
Detemir 1–2 None 6–24 
(dose-dependent)
Degludec 1 None 42
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Basal insulins and the cardiovascular system
with IGla.37 This difference could provide an explanation for 
the observed reduction of nocturnal and severe hypoglycemia 
with IDet compared with IGla in a 26-week trial in T1DM.38 
However, this difference could also be due to the fact that 
fewer patients on IDet reached the predefined target fast-
ing plasma glucose level (,126 mg/dL). In addition, more 
subjects needed twice-daily administration of basal insulin 
in the IDet group than in the IGla group. In T2DM patients, 
IDet and IGla provided similar results with regard to glucose 
control and hypoglycemic risk, the only detectable differ-
ences being for weight gain (lower with IDet) and insulin 
dose (lower with IGla).39–43
Degludec versus glargine
Due to its longer duration of action and lesser day-to-day 
variability in insulin absorption, IDeg has a potentially lower 
risk of hypoglycemia than other existing basal insulins.44 The 
incidence of nocturnal hypoglycemia is lower with IDeg than 
with IGla in both T1DM45–47 and T2DM.48–51 Meta-analyses 
of available trials suggest that, in T2DM, IDeg could also be 
associated with a reduction in the overall incidence of hypo-
glycemia and with a small improvement of fasting plasma 
glucose in comparison with IGla, with no difference in weight 
gain and a modest reduction of insulin doses.52–54
Degludec versus detemir
IDeg and IDet were directly compared in only two studies, 
both in T1DM, which showed a lower risk of nocturnal 
hypoglycemia and a greater weight gain with IDeg.55
Cardiovascular safety of insulin
Molecular mechanisms
Insulin receptors are widely represented on the surface of 
cells lining the vascular walls. The binding of insulin to 
insulin receptors triggers its phosphorylation and activation 
via intrinsic kinase activity, leading to tyrosine phosphoryla-
tion of insulin receptor substrate proteins and to activation 
of the phosphatidylinositol 3-kinase-Akt pathway, which 
activates endothelial nitric oxide (NO) synthase (eNOS).56 
The NO produced by eNOS decreases vascular tone and 
vascular smooth muscle cell proliferation and diminishes 
adhesion of inflammatory cells and platelet aggregation at 
the endothelium. Insulin also increases eNOS phosphoryla-
tion in human endothelial cells, improving eNOS activity 
and significantly reducing the production of reactive oxygen 
species. Furthermore, insulin modulates production of pros-
taglandins and endothelium-derived hyperpolarizing factors, 
which play a critical role as additional active vasodilators.57 
In addition to vasodilation, insulin can promote vasoconstric-
tion via activation of the mitogen-activated protein kinase 
(MAPK) cascade, which modulates insulin vasoconstriction 
and cell growth.
These effects of insulin are mediated, at least in part, 
by endothelin-1 and the vascular tissue renin-angiotensin-
aldosterone system. The balance between the proatherogenic 
and antiatherogenic effects of insulin showed significant 
differences based on the experimental model. In healthy 
individuals, insulin exerts a preponderance of vasodilatory 
and vasoprotective actions, but in insulin-resistant condi-
tions, the opposite vasoconstrictive effects seem to prevail58 
(Figure 1).
epidemiological studies
There is ongoing debate on the cardiovascular safety of 
insulin analogs. Epidemiological studies show a higher 
incidence of cardiovascular events in insulin-treated T2DM 
patients in comparison with those treated with non-insulin 
drugs.59,60 However, observational data do not allow causal 
inferences. In fact, patients receiving insulin are usually 
different from those treated with other glucose-lowering 
drugs; in most studies, they are older, have a longer duration 
of diabetes, and show a greater burden of complications and 
comorbidities. All these confounders can be adjusted for in 
statistical analysis; however, the possibility that insulin treat-
ment is a marker of greater severity of disease, which cannot 
be accounted for in statistical analysis, cannot be ruled out. 
For these reasons, assessment of the cardiovascular safety 
of insulin should be based on RCTs.
Clinical trials
To date, few intervention studies have evaluated the long-














Figure 1 Cardiovascular effects of insulin: molecular mechanisms. 
Abbreviations: Akt, Protein kinase B; iRS, insulin receptor substrate; Pi3K, 
phosphatidylinositol 3-kinase; eNOS, endothelial nitric oxide synthase; MAPK, 
mitogen-activated protein kinase; vSMC, vascular smooth muscle cell; ROS, reactive 
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major cardiovascular events among their principal endpoints. 
DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in 
Acute Myocardial Infarction) is an RCT comparing intensi-
fied insulin with standard care in patients with myocardial 
infarction. In this study, insulin produced a remarkable 
reduction of mortality, with a 2.3-year longer survival 
time at 20-year follow-up.61 However, the possibility that the 
reduction in mortality was determined by improved glucose 
control, rather than by a glucose-independent effect of insulin 
itself, should be considered. In addition, in the DIGAMI trial, 
intensified insulin treatment was initiated on hospital admis-
sion for myocardial infarction and maintained throughout 
follow-up; therefore, the design of the trial did not allow 
discrimination of whether the benefits were due to intensified 
treatment in the acute or chronic phase. A subsequent trial 
designed to elucidate this specific point, DIGAMI-2, failed in 
its objective, because the different treatment groups showed 
similar glucose control despite different glycemic targets. 
However, in an epidemiological analysis of this study, those 
receiving insulin showed a significant increase in non-fatal 
cardiovascular events (odds ratio 1.89, 95% confidence 
interval 1.35–2.63, P=0.0002).62
Some further information can be obtained from the 
BARI-2D (Bypass Angioplasty Revascularization Investiga-
tion 2 Diabetes) study, which compared an  insulin-providing 
(insulin and/or sulfonylureas) and an insulin-sensitizing 
(metformin and/or thiazolidinedione) regimen for glu-
cose control in T2DM patients affected by ischemic heart 
 disease. Five-year cardiovascular mortality and myocardial 
infarction rates did not differ significantly between the 
two treatment groups, with a small advantage for insulin 
sensitizers only in those undergoing coronary heart bypass 
grafting.63 Again, interpretation of results is problematic, 
because the other drugs used in the trial besides insulin 
could have either detrimental (sulfonylureas,64 thiazoli-
dinediones65) or beneficial (metformin66) effects on car-
diovascular risk.
In patients without prior cardiovascular events and at 
lower risk, the UK Prospective Diabetes Study failed to 
detect any significant benefit of insulin during the core phase 
of the trial,67 reaching a statistically significant reduction in 
the incidences of myocardial infarction and cardiovascular 
mortality in a subsequent 10-year follow-up.68 The trial was 
designed to verify the effect on all diabetic complications 
(microvascular plus macrovascular) of intensified glucose 
control obtained with different drugs (insulin, sulfonylureas, 
or metformin); therefore, the study was underpowered for the 
specific aim of assessing the cardiovascular effects of insulin. 
In addition, differences in outcomes could be due to divergent 
patterns of glucose control rather than to specific effects of 
each drug. When comparing insulin with other intensified 
treatments, cardiovascular morbidity and mortality rates 
were higher than with metformin, and not different from 
those with sulfonylureas.4
More recently, in the ORIGIN (Outcome Reduction 
with Initial Glargine Intervention) trial, IGla failed to show 
any cardiovascular harm or benefit over the comparator (no 
therapy or oral drugs) in patients with recent-onset diabetes 
and high cardiovascular risk. These results suggest that, from 
a cardiovascular standpoint, insulin treatment is neutral. 
However, the doses of IGla administered in this trial were 
rather low (with a median reaching 0.4 U/kg*day after 6 years 
in the 80% of patients still on treatment). Consequently, 
these results cannot exclude either beneficial or detrimental 
cardiovascular effects at higher doses.69
One of the main side effects of insulin therapy is hypo-
glycemia, which could be associated with an increase in 
cardiovascular risk. Experimental studies suggest that hypo-
glycemia may induce abnormal myocardial repolarization, 
QT prolongation, ventricular arrhythmias, and myocardial 
ischemia, probably mediated by adrenergic activation.70 
Epidemiological studies and exploratory analyses of trials 
supported the link between hypoglycemic events and cardio-
vascular outcomes.2,4,5 Notably, in the ACCORD (Action to 
Control Cardiovascular Risk in Diabetes) trial,71 an aggres-
sive approach to glucose control, with wide use of insulin 
and a high incidence of severe hypoglycemia, identified 
increased cardiovascular mortality, suggesting that aggressive 
management of hyperglycemia could lead to an increase in 
cardiovascular mortality.
Cardiovascular safety of basal 
insulin analogs
Molecular mechanisms
The mechanism of action of insulin analogs is identical to 
that of human insulin, ie, they bind to the same receptor, 
 producing the same cascade of intracellular signaling. The 
binding affinity for the insulin receptor significantly decreases 
from IGla and its metabolite, M1 (80%), to IDet (46%) and 
IDeg (14%).72 A study by Sciacca et al in three engineered 
cell models reported that basal insulin analogs, ie, IDet and 
IGla, produced a phosphorylation of both insulin receptor-A 
and insulin receptor-B similar to human insulin. However, 
significant differences were observed in intracellular signaling 
properties, with a higher extracellular-signal-regulated kinase 
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Basal insulins and the cardiovascular system
IGla induced phosphorylation of MAPK in a dose-
 dependent manner, comparable with that seen for human 
insulin, and demonstrated a comparable maximal response 
in many in vitro experimental studies while IDet-stimulated 
MAPK phosphorylation was substantially lower. The reduced 
phosphorylation of MAPK induced by IDet compared with 
IGla was more marked in L6 myocytes and vascular smooth 
muscle cells than in 3T3-L1 adipocytes, thus suggesting 
potential differences with regard to cardiovascular effects.74
Clinical trials on glargine and detemir
Long-acting insulin analogs produce a lower risk of hypo-
glycemia than NPH human insulin, in both T1DM and 
T2DM.17,18 A Cochrane review of RCTs in T2DM patients 
revealed that, in comparison with NPH insulin, the risk of 
severe hypoglycemia was 30% lower with IGla and 50% 
lower with IDet.75 If hypoglycemia plays a role in the 
development of cardiovascular disease, long-acting analogs 
could have a more favorable cardiovascular risk profile than 
human NPH insulin. Unfortunately, specific data on cardio-
vascular effects of long-term treatment with each analog 
are sparse. Presently, there is no available cardiovascular 
outcome trial with IDet. The only such study with IGla is 
the ORIGIN trial,69 which was described above. Based on 
the ORIGIN results, IGla should be considered safe for the 
cardiovascular system, at least when used at relatively low 
doses.  Unfortunately, in this trial, IGla was compared with 
non-insulin treatment and not with NPH; therefore, the study 
does not provide any information on possible differences in 
cardiovascular effects between IGla and human insulin.
Cardiovascular safety of degludec
The most recently introduced long-acting analog is IDeg, 
which appears to be associated with an even lower hypo-
glycemic risk than glargine.54 On February 8, 2013, the US 
Food and Drug Administration (FDA) denied approval for 
IDeg,76 in contrast with a previous decision of the European 
Medicines Agency,77 because of an increased risk (estimated 
hazard ratio 1.29, 95% confidence interval 0.88–1.88) of a 
composite endpoint including cardiovascular death, non-fatal 
myocardial infarction, non-fatal stroke, and unstable angina, 
relative to comparators. In the updated FDA composite 
endpoint analysis of major adverse cardiovascular events, 
excluding events of unstable angina pectoris, that included 
all completed trials as of May 1, 2012, incidence rates were 
1.41 per 100 events per patient year for IDeg + IDegAsp and 
0.90 per 100 events per patient year for the  comparator. In 
addition, if, together with the exclusion of unstable angina 
pectoris events, all major adverse cardiovascular events 
reported up to 30 days after drug discontinuation were 
included, the estimated hazard ratio for IDeg + IDegAsp 
versus comparators was 1.61 (95% confidence interval 
0.99–2.6). The decision contrasted with the FDA Endocri-
nologic and Metabolic Drugs Advisory Committee, which in 
November 2012 had unanimously recommended approval of 
the drug, although suggesting a post-approval cardiovascular 
outcomes trial. Available meta-analyses of publicly disclosed 
RCTs did not show any signal of increased risk of major 
cardiovascular events with IDeg in comparison with IGla.54 
The number of available cardiovascular events in trials with 
IDeg is very small, preventing any clear-cut conclusion. 
Notably, the analyses performed by the FDA, which diverged 
from the predefined analysis plans used for other approved 
diabetes drugs, achieved statistical significance only when 
using a very peculiar definition of cardiovascular events, ie, 
excluding unstable angina. In addition, in order to obtain a 
significant result, events occurred after drug discontinuation 
had to be included: since the duration of the trials is quite 
short, the difference in cardiovascular effects between IDeg 
and other basal insulins cannot reasonably be attributed to a 
differential action on long-term atherogenesis; on the other 
hand, if some immediate cardiovascular harm is hypoth-
esized, the inclusion of events after drug discontinuation is 
difficult to justify.
The iteration of statistical analyses leads, sooner or later, 
to a “significant” result. In fact, statistical significance was 
reached only after excluding unstable angina from major 
cardiovascular events and including cases that occurred 
during post-trial follow-up, when patients had returned to 
their previous basal insulin (usually glargine). It should 
also be considered that no biological rationale for a possible 
difference in cardiovascular effect of basal insulins has ever 
been proposed so far. The results of the FDA analysis could 
be the effect of chance. At the same time, it is important to 
have an accurate assessment of the cardiovascular safety 
of newer agents. A trial comparing the incidence of major 
cardiovascular events during therapy with insulin IDeg ver-
sus IGla in T2DM individuals at high risk of cardiovascular 
events (DEVOTE; NCT01959529)78 is currently ongoing; its 
results, expected a few years from now, will provide defini-
tive evidence on the cardiovascular safety of IDeg.
Conclusion
After about nine decades since its first clinical use, the long-
term cardiovascular effect of insulin is still partly unknown, 
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 complicates the issue, as those molecules could have, at least 
theoretically, cardiovascular effects different from those of 
human insulin. A wide range of experimental studies, while 
adding knowledge and insight on the molecular mechanisms 
of the action of insulin at the vascular level, do not allow any 
reliable prediction regarding the clinical effects of insulin 
and its analogs on cardiovascular risk.
In conclusion, although insulin is one of the most widely 
used drugs for the treatment of diabetes, we still need more 
data from clinical trials. Results of randomized studies com-
paring different analogs, such as in the ongoing DEVOTE 
trial,78 will provide information on which molecule has to 
be preferred as a basal insulin. However, we are still miss-
ing data assessing the effect of insulin on the incidence of 
cardiovascular events in comparison with other active drugs 
for T2DM. Such a trial, although not required by regulatory 
authorities, could be of great relevance in the definition of 
treatment algorithms for type 2 diabetes.
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